Figure 1.
Flow diagram of the study selection procedure.
Table 1.
Baseline characteristics of noncomparative studies assessing effect of combination therapy for unresectable HCC.
Table 2.
Baseline characteristics of comparative studies assessing effect of combination therapy for unresectable HCC.
Table 3.
Tumor Response, TTP and OS in the 10 noncomparative studies.
Figure 2.
Forest plot showing the associations of the time to progression (TTP) between TACE alone group and sorafenib combined with TACE group for patients with unresctable HCC.
The result of meta-analysis for TTP between TACE alone group and sorafenib combined with TACE group for patients with unresctable HCC. Studies are arranged by publication year. Forrest plot displayed as hazard ratio and 95% confidence intervals. (HR, hazard ratio; CI, confidence interval).
Figure 3.
Forest plot showing the associations of the overall survival (OS) between TACE alone group and sorafenib combined with TACE group for patients with unresctable HCC.
The result of meta-analysis for OS between TACE alone group and sorafenib combined with TACE group for patients with unresctable HCC.Studies are arranged by publication year. Forrest plot displayed as hazard ratio and 95% confidence intervals. (HR, hazard ratio; CI, confidence interval).
Table 4.
The adverse events experienced during combination therapy in 10 noncomparative studies.